Scientific Advisory Board Members
Function of the Scientific Advisory Board
Scientific Advisory Board Mission
The CHI Scientific Advisory Boards (SAB) is composed of internationally recognized scientists. The membership of the Scientific Advisory Board reflects the NIH’s research spectrum. The members of the Scientific Advisory Board are appointed by the Chair of the SAB after consultation with Scientific Directors (SD) from participating institutes. In justified cases, the Scientific Advisory Board – in agreement SD may enlist additional ad hoc experts. The role of the SAB is to provides strategic guidance and direction for CHI scientific priorities and research. The SAB plays a key role in guiding and prioritizing CHI research investment and serves as the executive committee for the evaluation of CHI proposals. The SAB is led and Chaired by the CHI scientific director.
Chair of the Scientific Advisory Board
The Chairperson of the Scientific Advisory Board is appointed by participating SDs. The Chairperson arranges the board meetings in agreement with CHI chief of operation and participating Institute’s Scientific Directors. The Chairperson presides over the meetings, prepares the board’s written report, and submits that report to NIH leadership.
Term of Office and Rotation of Scientific Advisory Board Membership
The term of office for each member of the Scientific Advisory Board is 5 years and can be extended by two years up to a maximum term of office of 7 years.
Frequency of Scientific Advisory Board Meetings
The Scientific Advisory Board will convene 3 times a year in a manner that coincide with project submissions cycles. In justified cases, SDs may arrange an extraordinary evaluation by the Scientific Advisory Board – of the CHI as a whole or of specific research areas. The date of each meeting is set by the CHI as early as possible, in consultation with the board members and the CHI chief of operation.
A Status Report is prepared by the CHI and sent to the board members in good time before the meeting and forms (in addition of project review) the written basis for the work of the Scientific Advisory Board. The Status Report describes the scientific research and projects completed, ongoing, and planned since the Scientific Advisory Board’s last evaluation, and gives an account of the Institute’s budget, the sources and deployment of funds.
Conflict of Interest
SAB members would have to recuse themselves for the evaluation of projects for which they are primary investigator or collaborators.
Scientific Board Advisory Members Bios
Yasmine Belkaid, Ph.D.
Dr. Belkaid is also the Scientific Director of CHI and her bio can be found under Leadership.
James M. Cherry, Ph.D.
Dr. Cherry is also the Chief of Operations of CHI and his bio can be found under Leadership.
Frank DeLeo, Ph.D.
Dr. DeLeo received his Ph.D. in microbiology from Montana State University in 1996, studying the molecular basis of superoxide generation by human neutrophils. He did his postdoctoral training in the area of innate immunity and infectious diseases in the Department of Medicine at the University of Iowa (1996–2000). Dr. DeLeo joined the staff at the NIAID Rocky Mountain Laboratories in 2000 as a tenure-track investigator. He served previously as Acting Chief (2007-2013) and Chief (2013-2015) of the Laboratory of Human Bacterial Pathogenesis. Dr. DeLeo was appointed to the NIH Senior Biomedical Research Service (2011-2017) and elected as an American Academy of Microbiology Fellow in 2017. He is currently Chief of the Laboratory of Bacteriology.
Pamela Guerrerio, M.D., Ph.D.
Pamela Guerrerio, M.D., Ph.D. is Chief of the Laboratory of Allergic Diseases at the National Institute of Allergy and Infectious Diseases (NIAID). Dr. Guerrerio graduated summa cum laude with a B.S. degree in biology from the University of Iowa and subsequently completed medical school and a Ph.D. in human genetics at Johns Hopkins University. She did her residency in pediatrics and fellowship in allergy and immunology at Johns Hopkins Hospital. Her research program is focused on understanding the key genetic, immunologic, and biochemical pathways that lead to the development of food allergy and other related diseases and how this information can be translated into therapeutic benefit.
Luigi D. Notarangelo, M.D.
Luigi D. Notarangelo is the Chief of the Laboratory of Clinical Immunology and Microbiology at NIAID. He has authored more than 500 publications; his research interest focuses on the characterization of the molecular and cellular bases of inborn errors of immunity and the development of novel therapeutic approaches for these disorders. He has contributed to the discovery of several genetic defects underlying immune deficiency, including JAK3, CD40LG, hypomorphic RAG, TTC7A, DOCK2, SASH3, PAX1, EXTL3 and FOXI3 deficiencies. His main current interest is centered on the definition of thymic cellular composition, diversity and transcriptional profile in health and disease both in humans and in mice. Dr. Notarangelo is a member of the National Academy of Medicine.
Robert Seder, M.D.
Dr. Seder is Chief of the Cellular Immunology Section, Acting Chief of the Clinical Trials and Vaccine Immunology Program and Acting Associate Director in the Vaccine Research Center, NIAID, NIH. Dr. Seder’s work has focused on the cellular and molecular mechanisms by which vaccines mediate protective immunity in animal models of HIV, malaria, tuberculosis, and cancer. Recently, Dr. Seder has focused his efforts on discovery of monoclonal antibodies to prevent malaria infection. Dr. Seder has successfully translated his scientific discoveries into “first in human” clinical trials using intravenous vaccination to generate protective immunity with an attenuated malaria vaccine and recently showed that a monoclonal antibody can prevent malaria infection following controlled human challenge or against intense seasonal transmission in Africa.
Over the 2 years, Dr. Seder led a series of pre-clinical, non-human primate studies using the Moderna mRNA vaccine developed by his colleagues at the Vaccine Research Center. This work provided the initial proof of principle for safety, immunogenicity and protection by mRNA 1273 in non-human primates required prior to the initiation of the Phase 3 clinical trial with the Moderna mRNA 1273 vaccine. Additional studies focused on defining immune correlates and mechanisms of protection, and his work provided the scientific basis for boosting humans against variants of concern.